TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the presence of Trk fusion, regardless of cancer type...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Kitap |
| Baskı/Yayın Bilgisi: |
MDPI AG,
2021-06-01T00:00:00Z.
|
| Konular: | |
| Online Erişim: | Connect to this object online. |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
| Yer Numarası: |
A1234.567 |
|---|---|
| Kopya Bilgisi 1 | Kütüphanede |